UK markets closed

Maravai LifeSciences Holdings, Inc. (MAR.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
6.90-0.25 (-3.50%)
At close: 09:55PM CEST
Full screen
Previous close7.15
Open7.15
Bid6.90 x N/A
Ask7.15 x N/A
Day's range6.90 - 7.15
52-week range4.20 - 12.50
Volume500
Avg. volume17
Market cap1.764B
Beta (5Y monthly)0.06
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center

    SAN DIEGO, May 13, 2024--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.

  • GlobeNewswire

    Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule

    SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June. On May 15, 2024, at 3:15 p.m. EST, Trey Martin, Chief Executive Officer and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the RBC Healthcare Conference in New York City, NY. On June 11, 2

  • GlobeNewswire

    Maravai LifeSciences Reports First Quarter 2024 Financial Results

    Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific InnovationSAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $64.2 million, Net loss of $(22.7) million, and Ad